31 Followers
24 Following
40 Posts
Immunologist and Medical Oncologist. Co-author of the cancer-immunity cycle and the immune set point with Ira Mellman; Opinions are my own.
LinkedInhttps://www.linkedin.com/in/daniel-chen-m-d-ph-d-4653842
Twitter (old)https://twitter.com/DanChenMDPhD

One of the important gaps in our understanding of biology comes from thinking of interactions as 2D diagrams rather than a series of biophysical interactions that occur, for instance, at the cell surface. Advances here will not only lead to more powerful therapeutics, it will usher in Directed Design and help us keep our human understanding up with #ai driven findings. #cancer #immunity #immunotherapy #biophysics
Immunity as biophysics at the surface of a T cell

https://lnkd.in/dmdGS8q5

LinkedIn

This link will take you to a page that’s not on LinkedIn

One of the important gaps in our understanding of biology comes from thinking of interactions as 2D diagrams rather than a series of biophysical interactions that occur, for instance, at the cell surface. Advances here will not only lead to more powerful therapeutics, it will usher in Directed Design and help us keep our human understanding up with #ai driven findings. #cancer #immunity #immunotherapy #biophysics
Immunity as biophysics at the surface of a T cell

https://lnkd.in/dmdGS8q5

LinkedIn

This link will take you to a page that’s not on LinkedIn

It was an enormous effort to put together- and an incredible sprint at the end to finish. A big thanks to my co-authors Ira Mellman Tom Powles Shannon Turley

And Thank You to Cell Press #immunity Fabiola Rivas Allison Bruce and all the authors that contributed to this special issue of Immunity!

We wrote the Cancer Immunity Cycle in 2013- and the scientific framework continues to hold up to time. After a decade of immense progress for patients with #cancer #immunotherapy we are excited to publish a 10Y update, reflecting the complexity in the TME.

https://authors.elsevier.com/c/1huvh3qNrUu448

We wrote the Cancer Immunity Cycle in 2013- and the scientific framework continues to hold up to time. After a decade of immense progress for patients with #cancer #immunotherapy we are excited to publish a 10Y update, reflecting the complexity in the TME.

https://authors.elsevier.com/c/1huvh3qNrUu448

A very important result for #cancer #immunotherapy #Tecentriq in #ASPS #sarcoma. Stunning Duration of Response and PFS - hints at insights into MOA and immunity. A breakthrough for the patients whom suffer from this disease, including the 77% that are under 40 Years of Age. #NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2303383?query=featured_home
Powerful debate between William Ho (In8 bio) and Kanya Rajangam (Senti Biosciences). Evenly matched with different styles. we all walked away a bit smarter. #io360nyc no holds barred. That's what makes the Debate Format special.
#cancer #immunotherapy #NKcells #gammadeltaTcells
Incredibly moving to see the positive results for IMbrave050, Tecentriq+Avastin in early stage HCC. Continues to highlight the relationship between #VEGF and #PDL1 #cancer #immunotherapy #HCC @genentech @Roche https://www.gene.com/media/press-releases/14981/2023-01-18/genentechs-tecentriq-plus-avastin-is-the
Genentech: Press Releases | Wednesday, Jan 18, 2023

Discover the latest news about our company, our products, our policies, and our people.

@EJohnWherry Incredibly important in understanding what problem we are solving for in immunology/immunotherapy.
One of the most impressive T cell papers in the past decades. A truly humbling experiment and incredibly important insights into T cell biology.
Dave Masopust and Vaiva Vezys
truly amazing. A must read for all T cell biologist (all immunologists really). #instantclassic. https://www.nature.com/articles/s41586-022-05626-9
Functional T cells are capable of supernumerary cell division and longevity - Nature

Through iterative cycles of viral challenge and rechallenge over ten years, mouse T cells are demonstrated to have essentially infinite potential for population expansion and longevity without malignant transformation or loss of functional competence.

Nature